Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.

Abstract: Provided are an oxime group-containing condensed heterocyclic compound or a salt thereof, preferably a condensed heterocyclic compound represented by general formula (1): (wherein the symbols are defined in the specification); an agricultural and horticultural insecticide comprising the compound or a salt thereof as an active ingredient; and a method for using the insecticide.

Abstract: Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.

Abstract: This invention relates to a Nanostructured Lipid Carrier (NLC) particle comprising a therapeutic agent encapsulated therein for ocular delivery of the therapeutic agent, wherein the Nanostructured Lipid Carrier comprises: (i) a solid outer shell comprising a solid lipid, and (ii) a liquid core comprising a liquid lipid; and wherein the core comprises the therapeutic agent. Compositions of the NLC particles, use of the NLC particles, methods of treatment or prevention of an eye disorder and an eye drop dispenser are also provided.

Abstract: The invention relates to an emulsion, e.g. in the form of a salve or a cream, with an aqueous phase and an oil phase, containing an NSAID, characterised in that: (a) the NSAID in the aqueous phase is in a concentration range that corresponds to half to a tenth of the standard concentration for these active substances; (b) the weight ratio of the water-to-oil phase in said emulsion is between the values 2.0 and 2.7; and (c) the pH value of the emulsion is not below the value 6.5 and not above 8.5, preferably in the region of between 7.0 and 8.0, particularly for application in the topical treatment of vaginal fungal infections.

Abstract: The embodiments disclosed and embraced by the present invention include silk-based products useful in the treatment, diagnosis, palliation, and/or amelioration of ocular diseases or conditions of the eye including those of the structures of the eye and surrounding tissue. Such silk-based products may effect beneficial outcomes alone or in combination with therapeutic modalities, compounds or medicaments.

Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

Abstract: A method of forming a core-shell polymer nanoparticle encapsulating an active agent is disclosed, including the use of a multi-solvent system in which to dissolve the active agent and a polymer prior to their precipitation using an antisolvent. The preferred use of an organic solvent system comprising two or more organic solvents allows for a high degree of control, as compared with the use of a single solvent, and enables the active agent to be precipitated more or less simultaneously with, or just prior to, the polymer.

Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, wherein the polyaphron dispersion comprises a continuous phase, a discontinuous phase and crisaborole.

Abstract: This disclosure generally relates to catheters, methods of enhancing the patency of an intravascular catheter and compositions, methods, devices and kits relating to the infusion of a catheter lock solution into an indwelling catheter. Disclosed compositions, methods, devices and kits aid in diminishing the effects of microbial infection in catheters and occlusion of the catheters. A representative lock solution includes about 10% sodium citrate and about 1.5% benzyl alcohol. The solution has a density approximating the density of blood for retention of the solution in a catheter during the lock period.

Abstract: A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, crosslinked network with a unique porosity. Furthermore, the barrier of the present invention is comprised of tunable biopolymers for controllable mechanical robustness and degradation. The barrier of the present invention effectively reduces unwanted adhesions using non-synthetic components.

Abstract: A novel composite biological agent based on a porous frame material, comprising porous frame materials and biomolecules. The porous frame materials cover a biological product, wherein the porous frame materials are metal-organic frame material (MOFs), covalent organic frame materials (COFs), and hydrogen-bonding organic frame materials (HOFs), and the biomolecules are any one or a combination of antibodies, enzymes, peptides, vaccines, nucleotides, and virus species. The composite biological agent uses the porous frame materials and biomolecules to form a porous frame material/biomolecule complex, and the biomolecules are coated to achieve the protection effect. Under the premise of remaining biomolecule activity, the system can achieve efficient separation and recovery of the porous materials and the biomolecules, so that the technical problems of synthesis, storage, release, etc. are solved, a good technical effect is achieved, and the biomolecules are effectively protected.

Abstract: Provided is a treating solution for soft contact lenses capable of imparting hydrophilicity and sustainability thereof to a soft contact lens surface. It has been found that a treating solution for soft contact lenses containing a copolymer that contains two kinds of monomers different from each other as constituent units at a specific ratio, and that has a specific weight-average molecular weight can impart excellent hydrophilicity and sustainability thereof.

Abstract: This invention relates to compositions and methods relating to a combination of naturally-occurring active ingredients useful for the regulation of kidney and excretory system function. The combination of active ingredients, comprising vitamin B6, vitamin E, iron, roundhead Lespedeza, birch leaf, and red bilberry, improves the function of kidney structures. The present invention may be used to achieve lower blood nitrogen content, including help to eliminate creatinine, urea, uric acid, by improving glomerular filtration and thus delaying hemodialysis. The present invention may be used to achieve a pronounced anti-inflammatory effect on the kidneys and the urinary tract. The present invention may also be used on its own or as a part of conventional treatment for a long time or indefinitely.

Abstract: The present invention relates to a cosmetic process which applies onto the skin a self-standing cosmetic sheet for the skin, comprising: at least one biocompatible and/or biodegradable hydrophobic polymer layer wherein the self-standing cosmetic sheet has a thickness of from 10 to 1000 nm, preferably from 30 to 500 nm, and more preferably from 50 to 300 nm. The cosmetic sheet according to the present invention may comprise at least one cosmetic active ingredient. The cosmetic sheet used in the present invention is very thin and not easily perceived on the skin; can be prepared with a variety of materials such as a biocompatible and/or biodegradable material; and can adhere well onto the skin without any adhesive layer so that it is less irritable or no irritable to the skin.

Abstract: A nicotine lozenge includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and nicotine or a derivative thereof dispersed in the soluble-fiber matrix. A nicotine lozenge may include at least 40 weight percent of soluble fiber. Soluble fiber in a nicotine lozenge may include maltodextrin. The nicotine lozenge is adapted to release the nicotine or a derivative thereof from the body when the body is received within the oral cavity of an adult consumer and exposed to saliva. A method of making nicotine lozenges includes forming a molten mixture of at least 40 weight percent soluble fiber, nicotine, and less than 15 weight percent water while maintaining a mixture temperature of less than 150° C. and portioning the molten mixture into a plurality of nicotine lozenges. The ingredients can be mixed to form the molten mixture in an extruder.

Abstract: The present disclosure relates to the use of alkali metal salts and preferably lithium chloride for treatment of Varroa destructor infestation of honey bees.

Abstract: A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. At least 90 weight % of the propellant component is 1,1-difluoroethane (HFA-152a).

Abstract: This disclosure is directed to ophthalmic suspensions for dry eye and other ocular indications that provide long-lasting on eye benefits. The disclosure provides methods of increasing lipid layer thickness and methods of lubricating an eye. The disclosure also provides methods of maintaining integrity of an eye's tear film layers which increases the eye's lipid layer thickness and methods of recreating or building one or more layers of an eye's tear film.

Abstract: This disclosure is directed to ophthalmic suspensions for dry eye and other ocular indications that provide long-lasting on eye benefits. The disclosure provides methods of increasing lipid layer thickness and methods of lubricating an eye. The disclosure also provides methods of maintaining integrity of an eye's tear film layers which increases the eye's lipid layer thickness and methods of recreating or building one or more layers of an eye's tear film.